Understanding Ozempic and Gastroparesis: What Michigan Patients Should Know

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Legal Guidance

If you or a loved one has been taking Ozempic and are experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering about the risk of gastroparesis. These symptoms can signal a condition where the stomach empties too slowly, and recent reports have raised questions about a possible connection to this medication. Building on decades of medical research into drug safety, this page reviews current evidence and clinical signals regarding Ozempic and gastroparesis.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. While its efficacy in glycemic control is well-documented, a growing body of evidence from clinical trials and post-marketing reports has raised concerns about its association with gastrointestinal adverse events, including gastroparesis. Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Understanding the clinical presentation, pharmacological mechanisms, and risk factors is critical for patients and healthcare providers, particularly in the context of potential legal claims.

Clinical Presentation and Diagnosis of Gastroparesis

Gastroparesis is diagnosed based on clinical symptoms and objective measures of delayed gastric emptying, typically via gastric emptying scintigraphy. Symptoms often include chronic nausea, vomiting (sometimes of undigested food), postprandial fullness, and abdominal discomfort. The condition can significantly impair quality of life and lead to nutritional deficiencies, dehydration, and weight loss. In severe cases, gastroparesis may require hospitalization for symptom management and nutritional support. The diagnosis is confirmed when symptoms persist for at least three months and gastric emptying studies show delayed emptying without evidence of obstruction.

Ozempic Pharmacology and Reported Adverse Effects

Ozempic works by mimicking the action of endogenous GLP-1, which stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. This mechanism is central to its therapeutic effect but also underlies its gastrointestinal side effects. According to the FDA-approved labeling, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo in placebo-controlled trials (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, the labeling lists other gastrointestinal adverse reactions with a frequency of less than 5%, including dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0% placebo, 2.7% 0.5 mg, 1.1% 1 mg), flatulence (0.8% placebo, 0.4% 0.5 mg, 1.5% 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% 0.5 mg, 1.5% 1 mg), and gastritis (0.8% placebo, 0.8% 0.5 mg, 0.4% 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways Linking Ozempic to Gastroparesis

The pharmacological action of Ozempic directly contributes to delayed gastric emptying. GLP-1 receptor agonists inhibit gastric motility and slow the rate at which the stomach empties its contents into the small intestine. While this effect is intended to improve glycemic control by reducing postprandial glucose excursions, it can become pathological in some individuals, leading to symptomatic gastroparesis. The mechanism involves activation of GLP-1 receptors on vagal afferent neurons and enteric neurons, which modulate gastric smooth muscle activity. Chronic use may lead to sustained inhibition of gastric peristalsis, potentially causing or exacerbating gastroparesis. The risk appears to be dose-dependent, as higher doses of Ozempic are associated with a greater incidence of gastrointestinal adverse reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Risk Anchors: Adequacy of Warnings and Attorney Considerations

The adequacy of warnings regarding Ozempic and gastroparesis is a central issue for affected patients. The current FDA-approved labeling does not explicitly list gastroparesis as a warning or precaution. Instead, it describes gastrointestinal adverse reactions in general terms, noting that nausea, vomiting, and diarrhea are common, especially during dose escalation. The labeling does not specifically address the risk of developing gastroparesis as a distinct condition. This omission may be significant for patients who experience severe or persistent symptoms that meet diagnostic criteria for gastroparesis. For patients who develop gastroparesis after using Ozempic, the question arises whether the manufacturer provided adequate information about this potential risk. In legal contexts, failure to warn about a known or reasonably foreseeable risk can form the basis of a product liability claim. For patients in Michigan considering legal action, several attorney-related considerations are relevant. First, the statute of limitations for personal injury claims in Michigan is generally three years from the date of injury or discovery of the injury. Patients should consult with an attorney promptly to ensure their claim is timely. Second, the causal link between Ozempic use and gastroparesis must be established through medical evidence, including documentation of symptoms, diagnostic testing, and temporal relationship. Third, the timeline between exposure and documented harm is critical. Patients who developed symptoms during dose escalation or within weeks to months of starting Ozempic may have a stronger case. The labeling indicates that gastrointestinal adverse reactions are most common during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting that early symptoms may be a warning sign. However, some patients may develop gastroparesis after prolonged use, and the labeling does not provide specific guidance on this point.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it related to Ozempic?

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism of action, which can cause or exacerbate gastroparesis in some individuals. Clinical trials have shown a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What should I do if I developed gastroparesis after taking Ozempic in Michigan?

If you developed gastroparesis after using Ozempic, it is important to seek medical attention for proper diagnosis and management. You should also consult with a qualified attorney in Michigan to discuss your legal rights. The statute of limitations for personal injury claims in Michigan is generally three years from the date of injury or discovery. An attorney can help evaluate whether you have a potential product liability claim based on inadequate warnings or other theories.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Ozempic

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.